Decision and Details
Japan Patent OfficeReceipt of a decision to grant a domestic patent relating to a kit for promoting neurite outgrowth and its use
To strengthen the intellectual property foundation for regenerative medicine pipelines, including KP8011, and accelerate company-sponsored clinical trials and partnering activities
There is no change to the earnings forecast for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Matter Covered | Receipt of a decision to grant a domestic patent relating to a kit for promoting neurite outgrowth and its use |
| Decision-Making Body | Japan Patent Office |
| Decision Date | 14 October 2026 (date the decision to grant the patent was received) |
| Quantity / scale | Application No.: 特願2023-524239 |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. |
| Reason | To strengthen the intellectual property foundation for regenerative medicine pipelines, including KP8011, and accelerate company-sponsored clinical trials and partnering activities |
| Related previous disclosures | A patent license agreement concluded in March 2024, and an exclusive license with the right to sublicense relating to “Neurosphere-inducing agent for spinal cord injury treatment and its use” in March 2021 |
| Future plans | The company plans to file the clinical trial notification for KP8011 during 2027. It will proceed with the technology transfer to Nikon Cell Innovation Co., Ltd., development of the clinical trial protocol, and partnership negotiations with pharmaceutical companies and others. It will also pursue patent filings overseas. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company believes that the decision to grant the patent will further strengthen the intellectual property foundation for regenerative medicine pipelines, including KP8011. It will also use the patent to promote company-sponsored clinical trials and accelerate partnering activities.